GlobeNewswire by notified

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies

Share

Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis

Mechelen, Belgium;23April 2021;06.01 CET;Galapagos NV (Euronext & Nasdaq: GLPG) today report that their collaboration partnerGilead Sciences K.K. (Gilead) and Eisai Co., Ltd. (“Eisai”)today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis (UC).Filgotinib is a new oral Janus kinase (JAK) inhibitor approved in Japan in September 2020 for the treatment of rheumatoid arthritis.

This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study evaluating the efficacy and safety of filgotinib for the induction and maintenance of remission in patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. This study showed a statistically significant higher proportion of patients treated with filgotinib 200mg once daily achieved clinical remission at week 10 and maintained remission at week 58 compared with placebo. No new safety risks were identified.

Ulcerative colitis is a chronic disease characterized by inflammation of the lining of the mucosa of the colon and rectum. The prevalence of ulcerative colitis has been increasing in recent years, and it has a significant impact on the quality of life of more than 2 million people around the world. Even with treatment, defecation urgency, incontinence, recurrent bloody diarrhea, frequent bowel movements, abdominal pain, insomnia and fatigue are common. Ulcerative colitis is one of the intractable diseases1 designated by the Ministry of Health, Labour and Welfare in Japan. According to a nationwide survey, the estimated number of patients with ulcerative colitis in Japan in 2014 was 219,685. The annual prevalence rate per 100,000 was 172.9 (192.3 men, 154.5 women).2

About filgotinib
Filgotinib is approved and marketed as Jyseleca (200mg and 100mg tablets) in the Europe Union, Great Britain and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). This definition from the European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu. The interview form from the Japanese Ministry of Health, Labour and Welfare is available at www.info.pmda.go.jp. The Great Britain Summary of Product Characteristics is available at www.medicines.org.uk/emc. Applications have been submitted to the EMA, the MHRA and the PMDA for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent and are currently under review.  Filgotinib is not approved in any other countries.

About the filgotinib collaboration
Gilead and Galapagos NV are collaborative partners in the global development and commercialization of filgotinib. Galapagos will be responsible for the commercialization of filgotinib in Europe (transition anticipated to be completed by end of 2021), while Gilead will remain responsible for filgotinib outside of Europe, including in Japan, where filgotinib is co-marketed with Eisai. Filgotinib in UC has been filed in Europe and Japan and a global Phase 3 program is ongoing in Crohn’s Disease. More information about clinical trials can be accessed at www.clinicaltrials.gov.

About Galapagos
Galapagos NV discovers, develops and commercializes small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. Our ambition is to become a leading global biotech company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Global Head of Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900
communications@glpg.com

Forward-looking statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent risks associated with clinical trial and product development activities, competitive developments, and regulatory approval requirements, including the risk that data from the ongoing and planned clinical research programs with filgotinib may not support registration or further development in UC or other indications due to safety, efficacy or other reasons, the timing or likelihood of regulatory authorities approval of marketing authorization for filgotinib for UC or any other indications, such regulatory authorities requiring additional studies, statements relating to interactions with the regulatory authorities, Galapagos’ strategic R&D ambitions and potential changes of such ambitions, Galapagos’ reliance on collaborations with third parties, including the collaboration with Gilead for filgotinib, the uncertainty regarding estimates of the commercial potential of filgotinib, the timing of and the risks related to implementing the amendment of our arrangement with Gilead for the commercialization and development of Jyseleca (filgotinib), the uncertainties relating to the impact of the COVID-19 pandemic, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2020 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.

1Japan promotes research related to intractable diseases and financially supports patients with these diseases. Intractable diseases are designated as those that fulfill the following criteria: (1) rarity (affecting less than 0.1% of the population in Japan), (2) unknown etiology, (3) lack of effective treatment, (4) necessity of long-term treatment, and (5) existence of objective diagnostic criteria and not necessarily equal to rare diseases in other countries. Neurol Med Chir (Tokyo). 2017 Jan; 57(1): 1–7. Published online 2016 Sep 21. doi: 10.2176/nmc.st.2016-0135

2Murakami Y, Nishiwaki Y, Oba MS, Asakura K, Ohfuji S, Fukushima W, et al. Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol 2019;54 (12):1070-7

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sword Group: NOTICE OF CONVOCATION TO THE SHAREHOLDERS FOR THE ANNUAL ORDINARY GENERAL MEETING OF THE COMPANY28.3.2024 18:00:00 CET | Press release

General Meeting on April 29, 2024, at 11:00 am at the registered office to deliberate on the following agenda: Under the authority of the General Meeting acting under the quorum and majority conditions of an Ordinary General Meeting: - Reading of the management report of the Board of Directors including the group management report and feedback on the conclusion of agreements referred to in article L.441-7 of the amended law of August 10, 1915, for the financial year ended December 31, 2023; - Reading of the report of the approved statutory auditor on the 2023 annual accounts, the group's consolidated financial statements, and on the execution of its mission; - Approval of the statutory accounts as of December 31, 2023; - Approval of the consolidated accounts as of December 31, 2023; - Allocation of the statutory exercise results as of December 31, 2023; - Discharge to the directors for their management for the financial year 2023; - Renewal of Mr. Jacques Mottard's director term; - Ren

Sword Group: H2 2023 Report of the Liquidity Agreement28.3.2024 18:00:00 CET | Press release

Sword Group - H2 Report of the Liquidity Agreement contracted with ODDO BHF from 01/07/2023 au 31/12/2023 Under the liquidity contract awarded by Sword Group to ODDO BHF, as of 31/12/2023, the following resources appeared on the account of liquidity: 8,959 shares €359,040 - Number of transactions executed during the semester at purchase: 1,116 - Number of transactions executed during the semester on sale: 1,080 - Volume exchanged over the semester upon purchase: 34,943 shares for an amount of €1,319,183 - Volume exchanged over the semester for sale: 38,733 shares for an amount of €1,455,889 As a reminder, during the last balance sheet of 30/06/2023, the following resources appeared in the liquidity account: 12,749 shares €353,334 The implementation of the liquidity contract is carried out in accordance with AMF Decision No. 2018-01 dated July 2, 2018, establishing liquidity contracts on equity securities as accepted market practice. About Sword Group Sword has 3,000+ IT/Digital & Softw

Sword Group: Availability of the 2023 Financial Report28.3.2024 18:00:00 CET | Press release

Sword Group - Availability of the 2023 Financial Report According to the current regulations, Sword Group announces that its 2023 Financial Report has been made available to the public. It was sent to the Commission de Surveillance du Secteur Financier (CSSF) and was also filed with the Luxembourg Stock Exchange. It can be viewed and downloaded on the website of the company:Regulated Information Dividend €1.7 gross per shre Pending approval at the Annual General Meeting on April 29. Ex-date: April 30, 2024 - Payment: May 3, 2024 Calendar 25/04/24 | 2024 First Quarter Revenue 18/07/24 | 2024 Second Quarter Revenue About Sword Group Sword has 3,000+ IT/Digital specialists present over 5 continents to accompany you in the growth of your organisation in the digital age. As a leader in technological and digital transformation, Sword has a solid reputation in software publishing and in complex IT & business project management. Sword optimises your processes and enhances your data. Contact At

Sword Group: Information on the Number of Shares and Voting Rights at 29/02/202428.3.2024 18:00:00 CET | Press release

INFORMATION ON THE NUMBER OF SHARES AND VOTING RIGHTS AT 29/02/2024 Total Number of Shares: 9,544,965 Number of theoretical voting rights: 9,544,965 Number of exercisable voting rights: 9,398,264 Dividend €1.7 gross per shre Pending approval at the Annual General Meeting on April 29. Ex-date: April 30, 2024 - Payment: May 3, 2024 Calendar 25/04/24 | 2024 First Quarter Revenue 18/07/24 | 2024 Second Quarter Revenue About Sword Group Sword has 3,000+ IT/Digital specialists present over 5 continents to accompany you in the growth of your organisation in the digital age. As a leader in technological and digital transformation, Sword has a solid reputation in software publishing and in complex IT & business project management. Sword optimises your processes and enhances your data. Contact Attachment Sword Group SE Number of Shares & voting Rights published on 28032024

Sword Group: Availability of preparatory documents for the Ordinary General Meeting of 29 April 202428.3.2024 18:00:00 CET | Press release

The Ordinary General Meeting of Shareholders of Sword Group SE will be held at 11 a.m. on 29 April 2024. The notice of meeting including the agenda was published in the RESA (Recueil électronique des sociétés et associations) and in the Luxemburger Wort on 28 March 2024. The terms and conditions for attending and voting at this meeting are set out in this notice. The documents and information that must be provided at the General Meeting, together with the single form for participation, postal voting and proxy (the "Single Form"), are available on the Company's website here and at the registered office for an uninterrupted period commencing on the day of publication of this notice and ending on the day after the General Meeting. Upon presentation of their shares, shareholders may obtain copies of the documents free of charge under the applicable legal conditions. Registered shareholders must send the Company the duly completed, dated and signed Single Form, together, where applicable, w

HiddenA line styled icon from Orion Icon Library.Eye